E
Elias Jabbour
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1303
Citations - 29725
Elias Jabbour is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 71, co-authored 1108 publications receiving 21641 citations. Previous affiliations of Elias Jabbour include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
Nitin Jain,Michael J. Keating,P. D. Thompson,Alessandra Ferrajoli,Jayastu Senapati,Jan A. Burger,Gautam Borthakur,Koichi Takahashi,Zeev Estrov,Marina Konopleva,Koji Sasaki,Tapan M. Kadia,Naveen Pemmaraju,Naval Daver,Elias Jabbour,Courtney D. DiNardo,Yesid Alvarado,Musa Yilmaz,Prithviraj Bose,Maro Ohanian,Rashmi Kanagal-Shamanna,Keyur Patel,Jeffrey L. Jorgensen,Sa A. Wang,Sameh Nassar,Naveen Kumar Garg,Hyunsoo Hwang,Xuemei Wang,Nichole Cruz,Ana Ayala,William Plunkett,Hagop M. Kantarjian,Varsha Gandhi,William G. Wierda +33 more
TL;DR: Jain et al. as discussed by the authors reported results of the first-line cohort of a phase II trial of combined IBR and VEN for high-risk pts with CLL (Jain, NEJM 2019, JAMA Oncology 2021).
Journal ArticleDOI
Ruxolitinib (RUX) in combination with azacytidine (AZA) in patients (pts) with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs).
Rita Assi,Jorge E. Cortes,Naveen Pemmaraju,Elias Jabbour,Prithviraj Bose,Tapan M. Kadia,Courtney D. DiNardo,Lingsha Zhou,Sherry Pierce,Stephanie Van Derbur,Carla Tuttle,Gautam Borthakur,Zeev Estrov,Guillermo Garcia-Manero,Hagop M. Kantarjian,Srdan Verstovsek,Naval Daver +16 more
TL;DR: Combining RUX and AZA may target distinct manifestations of MDS/MPNs with clinical trials exclusively focusing on pts with MDS or MPNs lacking.
Journal ArticleDOI
Current and Future Clinical Strategies in the Management of Chronic Myeloid Leukemia
TL;DR: This review summarizes recent advances in the treatment of CML over the past decade, with an emphasis on tyrosine kinase inhibitor therapy.
Journal ArticleDOI
Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection
Marina Konopleva,Gautam Borthakur,Peter F. Thall,Andrew Coveler,Farhad Ravandi,Elias Jabbour,Hoang Q. Nguyen,Juliana Benito,Yongchuan Gu,William R. Wilson,Teresa J. Melink,Hagop M. Kantarjian,John Gutheil,Elihu H. Estey +13 more
TL;DR: Gutheil et al. as discussed by the authors showed that the pre-prodrug PR104 is rapidly converted systemically to its alcohol metabolite PR-104A, a bioreductive prodrug that undergoes metabolic activation to DNA-crosslinking nitrogen mustard metabolites.